Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 4/2012

01.04.2012 | Original Article

Intraoperative Detection of Disappearing Colorectal Liver Metastases as a Predictor of Residual Disease

verfasst von: Alessandro Ferrero, Serena Langella, Nadia Russolillo, Luca Vigano’, Roberto Lo Tesoriere, Lorenzo Capussotti

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the intraoperative detection rate of residual liver metastases after chemotherapy and to assess the correlation between disappeared liver metastases (DLMs) upon preoperative imaging and complete pathological response.

Methods

Between February 2004 and December 2008 clinicopathological data of 292 consecutive patients who underwent liver resection for colorectal liver metastases were prospectively collected and analyzed in a “per lesion” study. Thirty-three patients with 67 DLMs were included.

Results

During laparotomy, we identified 45 out of 67 DLMs (67%). Six DLMs were detected by macroscopic liver examination (9%) and 39 (58%) by intraoperative ultrasound (IOUS). Overall, persistent microscopic residual disease at pathological examination of the resected specimen or recurrence in situ identified during the follow-up were observed in 41 (61.2%) of 67 LMs that had shown a complete response by imaging. At multivariate analysis moderate or severe hepatic steatosis (p = 0.016), subglissonian localization of nodules (p = 0.019) and residual microscopic disease (p = 0.0006) were associated with IOUS detection of residual metastases. Preoperative chemotherapy with more than six cycles (p = 0.022) and intraoperative detection of nodules by IOUS (p = 0.001) were independent predictors of residual disease.

Conclusions

Systematic US exploration of the liver leads to increase the intraoperative detection rate of DLMs. Furthermore, the majority of DLMs identified by IOUS presents residual disease at pathological examination and should be treated.
Literatur
1.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, et. al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007–1016.PubMedCrossRef Nordlinger B, Sorbye H, Glimelius B, et. al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371:1007–1016.PubMedCrossRef
2.
Zurück zum Zitat Adam R, Wicherts DA, de Haas RJ, et. al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829–1835.PubMedCrossRef Adam R, Wicherts DA, de Haas RJ, et. al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27:1829–1835.PubMedCrossRef
3.
Zurück zum Zitat Ribero D, Wang H, Donadon M et. al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761–7.PubMedCrossRef Ribero D, Wang H, Donadon M et. al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 110:2761–7.PubMedCrossRef
4.
Zurück zum Zitat Folprecht G, Gruenberger T, Bechstein WO, et. al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38–47.PubMedCrossRef Folprecht G, Gruenberger T, Bechstein WO, et. al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11:38–47.PubMedCrossRef
5.
Zurück zum Zitat Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17:492–501.PubMedCrossRef Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann Surg Oncol 2010; 17:492–501.PubMedCrossRef
6.
Zurück zum Zitat Chun YS, Vauthey JN, Boonsirikamchai P, et. al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338–2344.PubMedCrossRef Chun YS, Vauthey JN, Boonsirikamchai P, et. al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302:2338–2344.PubMedCrossRef
7.
Zurück zum Zitat Adam R, Wicherts DA, de Haas RJ, et. al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26:1635–41.PubMedCrossRef Adam R, Wicherts DA, de Haas RJ, et. al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26:1635–41.PubMedCrossRef
8.
Zurück zum Zitat Rubbia-Brandt L, Giostra E, Brezault C, et. al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18:299–304.PubMedCrossRef Rubbia-Brandt L, Giostra E, Brezault C, et. al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18:299–304.PubMedCrossRef
9.
Zurück zum Zitat Blazer DG III, Kishi Y, Maru DM, et. al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26:5344–5351.PubMedCrossRef Blazer DG III, Kishi Y, Maru DM, et. al. Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26:5344–5351.PubMedCrossRef
10.
Zurück zum Zitat Dy GK, Krook JE, Green EM, et. al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: Results from Intergroup N9741. J Clin Oncol 2007; 25:3469–3474.PubMedCrossRef Dy GK, Krook JE, Green EM, et. al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: Results from Intergroup N9741. J Clin Oncol 2007; 25:3469–3474.PubMedCrossRef
11.
Zurück zum Zitat Benoist S, Brouquet A, Penna C, et. al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939–3945.PubMedCrossRef Benoist S, Brouquet A, Penna C, et. al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939–3945.PubMedCrossRef
12.
Zurück zum Zitat Elias D, Goere D, Boige V, et. al. Outcome of posthepatectomy missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188–3194.PubMedCrossRef Elias D, Goere D, Boige V, et. al. Outcome of posthepatectomy missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188–3194.PubMedCrossRef
13.
Zurück zum Zitat Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250:935–942.PubMedCrossRef Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250:935–942.PubMedCrossRef
14.
Zurück zum Zitat Auer RC, White RR, Kemeny NE, et. al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116:1502–1509.PubMedCrossRef Auer RC, White RR, Kemeny NE, et. al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116:1502–1509.PubMedCrossRef
15.
Zurück zum Zitat van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned? J Gastrointest Surg 2010; 14:1691–700.PubMedCrossRef van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing Colorectal Liver Metastases after Chemotherapy: Should we be Concerned? J Gastrointest Surg 2010; 14:1691–700.PubMedCrossRef
16.
Zurück zum Zitat Carpenter S, Fong Y. Management of disappearing colorectal hepatic metastases. Adv Surg 2010; 44:269–79.PubMedCrossRef Carpenter S, Fong Y. Management of disappearing colorectal hepatic metastases. Adv Surg 2010; 44:269–79.PubMedCrossRef
17.
Zurück zum Zitat Thomay AA, Charpentier KP. Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy. J Surg Oncol 2010; 102:1002–8.PubMedCrossRef Thomay AA, Charpentier KP. Optimizing resection for “responding” hepatic metastases after neoadjuvant chemotherapy. J Surg Oncol 2010; 102:1002–8.PubMedCrossRef
18.
Zurück zum Zitat Choti MA, Kaloma F, de Oliveira ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM. Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg 2008; 143:29–34.PubMedCrossRef Choti MA, Kaloma F, de Oliveira ML, Nour S, Garrett-Mayer ES, Sheth S, Pawlik TM. Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg 2008; 143:29–34.PubMedCrossRef
19.
Zurück zum Zitat The Brisbane 2000 Terminology of Liver Anatomy and Resection. Terminology Committee of The International Hepato-Pancreato-Biliary Association. HPB 2000; 2:333–339. The Brisbane 2000 Terminology of Liver Anatomy and Resection. Terminology Committee of The International Hepato-Pancreato-Biliary Association. HPB 2000; 2:333–339.
20.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et. al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 4:1313–1321.CrossRef Kleiner DE, Brunt EM, Van Natta M, et. al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 4:1313–1321.CrossRef
21.
Zurück zum Zitat Robinson PJA. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009; 19:1752–1762.PubMedCrossRef Robinson PJA. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009; 19:1752–1762.PubMedCrossRef
22.
Zurück zum Zitat Znajda TL, Hayashi S, Horton PJ, et. al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 2006; 10:483–9.PubMedCrossRef Znajda TL, Hayashi S, Horton PJ, et. al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 2006; 10:483–9.PubMedCrossRef
23.
Zurück zum Zitat Foroutani A, Garland AM, Berber E, et. al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. Arch Surg 2000; 135:933–8.PubMedCrossRef Foroutani A, Garland AM, Berber E, et. al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. Arch Surg 2000; 135:933–8.PubMedCrossRef
24.
Zurück zum Zitat Torzilli G, Makuuchi M. Intraoperative ultrasonography in liver cancer. Surg Oncol Clin N Am 2003; 12:91–103.PubMedCrossRef Torzilli G, Makuuchi M. Intraoperative ultrasonography in liver cancer. Surg Oncol Clin N Am 2003; 12:91–103.PubMedCrossRef
25.
Zurück zum Zitat Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77:2008–2011.PubMedCrossRef Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998; 77:2008–2011.PubMedCrossRef
26.
Zurück zum Zitat Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12:722–7.PubMedCrossRef Miyake K, Hayakawa K, Nishino M, Morimoto T, Mukaihara S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005; 12:722–7.PubMedCrossRef
27.
Zurück zum Zitat Vauthey JN, Pawlik TM, Ribero D, et. al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065–2072.PubMedCrossRef Vauthey JN, Pawlik TM, Ribero D, et. al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065–2072.PubMedCrossRef
28.
Zurück zum Zitat Angliviel B, Benoist S, Penna C, et. al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 2009; 16:1247–53.PubMedCrossRef Angliviel B, Benoist S, Penna C, et. al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol 2009; 16:1247–53.PubMedCrossRef
29.
Zurück zum Zitat Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11:1112–1119.PubMedCrossRef Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007; 11:1112–1119.PubMedCrossRef
30.
Zurück zum Zitat Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145:340–5.PubMedCrossRef Glazer ES, Beaty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145:340–5.PubMedCrossRef
31.
Zurück zum Zitat Lubezky N, Metser U, Geva R, et. al. The role and limitations of 18-fluoro-2-deoxy-d -glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007; 11:472–8.PubMedCrossRef Lubezky N, Metser U, Geva R, et. al. The role and limitations of 18-fluoro-2-deoxy-d -glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007; 11:472–8.PubMedCrossRef
32.
Zurück zum Zitat Bipat S, van Leewen MS, Comans EFI, Pijl MEJ, Bossuyt BMM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging and PET for diagnosis—meta-analysis. Radiology 2005; 237:123–31.PubMedCrossRef Bipat S, van Leewen MS, Comans EFI, Pijl MEJ, Bossuyt BMM, Zwinderman AH, Stoker J. Colorectal liver metastases: CT, MR imaging and PET for diagnosis—meta-analysis. Radiology 2005; 237:123–31.PubMedCrossRef
33.
Zurück zum Zitat Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31:19–31.PubMedCrossRef Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L, Giovagnoni A. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31:19–31.PubMedCrossRef
34.
Zurück zum Zitat Kulemann V, Schima W, Tamandl D, et. al. Preoperative detection of colorectal liver metastases: MDCT or MRI? Eur J Radiol 2011; 79:e1-6.PubMedCrossRef Kulemann V, Schima W, Tamandl D, et. al. Preoperative detection of colorectal liver metastases: MDCT or MRI? Eur J Radiol 2011; 79:e1-6.PubMedCrossRef
35.
Zurück zum Zitat Conlon R, Jacobs M, Dasgupta D, Lodge JP. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J of Ultrasound 2003; 16:21–16. Conlon R, Jacobs M, Dasgupta D, Lodge JP. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J of Ultrasound 2003; 16:21–16.
36.
Zurück zum Zitat van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, Choti MA. The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative ultrasonography. Arch Surg 2010; 147:661–7. van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, Choti MA. The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative ultrasonography. Arch Surg 2010; 147:661–7.
37.
Zurück zum Zitat Torzilli G, Del Fabbro D, Palmisano A et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9:1148–53PubMedCrossRef Torzilli G, Del Fabbro D, Palmisano A et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9:1148–53PubMedCrossRef
38.
Zurück zum Zitat Leen E, Ceccotti P, Moug SJ et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg 2006; 243:236–40.PubMedCrossRef Leen E, Ceccotti P, Moug SJ et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg 2006; 243:236–40.PubMedCrossRef
39.
Zurück zum Zitat Torzilli G, Botea F, Procopio F et al. Use of contrast-enhanced intraoperative ultrasonography during liver surgery for colorectal cancer liver metastases—its impact on operative outcome. Analysis of a prospective cohort study. Eur J Cancer 2008; 6:16–23 Torzilli G, Botea F, Procopio F et al. Use of contrast-enhanced intraoperative ultrasonography during liver surgery for colorectal cancer liver metastases—its impact on operative outcome. Analysis of a prospective cohort study. Eur J Cancer 2008; 6:16–23
40.
Zurück zum Zitat Kishi Y, Zorzi D, Contreras CM, et. al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17:2870–6.PubMedCrossRef Kishi Y, Zorzi D, Contreras CM, et. al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010; 17:2870–6.PubMedCrossRef
Metadaten
Titel
Intraoperative Detection of Disappearing Colorectal Liver Metastases as a Predictor of Residual Disease
verfasst von
Alessandro Ferrero
Serena Langella
Nadia Russolillo
Luca Vigano’
Roberto Lo Tesoriere
Lorenzo Capussotti
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 4/2012
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-011-1810-5

Weitere Artikel der Ausgabe 4/2012

Journal of Gastrointestinal Surgery 4/2012 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.